stock faces transition as covid vaccine demand wanes By Investing.com
Moderna , Inc. (NASDAQ:), the biotechnology company that rose to prominence with its COVID-19 vaccine, is navigating a critical transition period as it seeks to diversify its product portfolio and maintain its position in the competitive vaccine market. With a current market capitalization of $16.1 billion and a stock price of $42.03, the company has experienced significant challenges, including a 70.5% decline in share price over the past six months. As the company moves beyond its reliance on COVID-19 vaccine revenues, investors and analysts are closely watching its pipeline developments and financial performance to gauge its long-term prospects. According to InvestingPro analysis, the company currently appears undervalued based on…
